Panayiotis Anastasiou

Nov 1, 2024 | science.org | Spencer Shelton |Megan Cole |Mengjie Zhang |Panayiotis Anastasiou

AbstractKirsten rat sarcoma virus (KRAS)–G12C inhibition causes remodeling of the lung tumor immune microenvironment and synergistic responses to anti–PD-1 treatment, but only in T cell infiltrated tumors. To investigate mechanisms that restrain combination immunotherapy sensitivity in immune-excluded tumors, we used imaging mass cytometry to explore cellular distribution in an immune-evasive KRAS mutant lung cancer model.

Apr 13, 2024 | biorxiv.org | Megan Cole |Panayiotis Anastasiou |Claudia Lee |Chris Moore

AbstractWe recently showed that lung tumor specific KRAS-G12C inhibition causes remodelling of the tumor immune microenvironment from cold to hot. As a result, KRAS-G12C inhibition is able to synergise with anti-PD-1 treatment, but only in tumor models that were already moderately responsive to immune checkpoint blockade at baseline.

Jan 16, 2024 | biorxiv.org | Christopher Moore |Sareena Rana |Andrea de Castro |Panayiotis Anastasiou

AbstractMutant selective drugs targeting the inactive, GDP-bound form of KRASG12C have been approved for use in lung cancer, but responses are short-lived due to rapid development of resistance. In this study we use a novel covalent tri-complex inhibitor, RMC-4998, that targets RASG12C in its active, GTP-bound form to investigate treatment of KRAS mutant lung cancer in various immune competent mouse models.